Nasal sprays can treat congestion and other symptoms of seasonal allergies or a cold. They work by delivering a fine mist of medication into your nostrils. Since the lining of your nose is rich with ...

The U.S. Food and Drug Administration (FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with treatment ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant depression. This marks a significant advancement in depression treatment ...

The results? A nasal spray of oxytocin significantly reduced acute feelings of loneliness in participants, especially during group therapy sessions, even months after treatment. In the study ...

Now, the Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray, Spravato, to be used as a standalone treatment for people with severe depression who haven't ...

Fluticasone propionate is under clinical development by Eupraxia Pharmaceuticals and currently in Phase II for Osteoarthritis Pain. According to GlobalData, Phase II drugs for Osteoarthritis Pain have ...

Wed, January 22, 2025 at 1:29 PM UTC ...

The drug Spravato is a nasal spray made by Johnson and Johnson. It was first approved in 2019 with an oral antidepressant. Now the drug can be used on its own. The medication is related to ketamine — ...